Abstract
RNA N6-methyladenosine (m6A) methylation is known to be the most popular RNA modification in animals. Many research reports have elaborated on the effects of m6A regulators in medical practice, such as diagnosis, prognosis, and treatment. M6A modification has evident impacts on many aspects of RNA metabolism, just like RNA splicing, processing, translation, and stability. M6A also has a magnificent role in numerous types of cancers. We analyzed the prostate cancer datasets, from The Cancer Genome Atlas (TCGA) database, for every recognized m6A regulator in their gene expression, DNA methylation status and copy number variations (CNVs). We also systematically analyzed the relationship between different m6A regulators and the prognosis of prostate cancer. The results illustrated considerable differences in the expression of various m6A regulators between the prostate and normal cancer samples. At the same time, there were evident differences in the expression of various m6A regulators in prostate cancers with different Gleason scores. Subsequently, we determined CBLL1, FTO, YTHDC1, HNRNPA2B1 as crucial m6A regulators of prostate cancer. Premised on the expression of CBLL1, we also identified potential therapeutic agents for prostate cancer, and knockdown of FTO prominently inhibited prostate cells migration and invasion in vitro experiment.
Highlights
Prostate cancer (PCa) is the most commonly occurring malignant tumor of the male genitourinary system and ranks second among the common malignant tumors in men worldwide
This article primarily concentrates on the physiological functions of m6A modification as well as the m6A regulators involved in prostate cancer
Prostate cancer was classified into three cohorts with different prognosis
Summary
Prostate cancer (PCa) is the most commonly occurring malignant tumor of the male genitourinary system and ranks second among the common malignant tumors in men worldwide. Its incidence rate is highest in the United States (Siegel et al, 2021). It had around 1.1 million diagnoses in 2012 worldwide, which accounted for 15% of the diagnosed malignant tumors (Ferlay et al, 2015). Despite the recent development of novel treatments, patients with advanced PCa have a high death rate (McNevin et al, 2021). Identifying appropriate biomarkers is essential for the early diagnosis, treatment, and prognosis of prostate cancer. Histological grading of prostate cancer is an important parameter for predicting the treatment and prognosis response. The Gleason grade is assigned based on the architecture and arrangement of the malignant cells within the tumor.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
